Europe Glycomic Therapeutics Market
Historic Data:    |   Base Year: 2023   |   Forecast Period: 2024-2031
Forecast to 2028 - COVID-19 Impact and Regional Analysis ByClass (Isolated and Synthetic), Structures [Glycoproteins, Targeting Sialic Acid, Proteoglycans, Targeting Glycosaminoglycans, Glycosylphosphatidylinositol (GPI)-Anchored Proteins & Heparin Based Glycans, Targeting Glycosphingolipids, and Others], Indications (Thrombosis & Chemoprophylaxis, Anaemia, Anti-Adhesive & Anti-Inflammatory, Cataracts, Gaucher’s Disease, MPS-1 & IV, Cancer, Alzheimer’s Disease, Influenza Type A & B, and Others), Mode of Action [Inhibits Neuraminidase, Inhibits Heparanase and Selectins and Blocks Interactions Between Growth Factors and Heparan Sulfate, Erythropoietin & Enzyme Replacement Therapy (ERT), Tissue Plasminogen Activator, Inhibits Glucosylceramide Synthas Interleukin 1 and 2 and 3, Beta & Gamma Interferons, and Others]

No. of Pages: 222    |    Report Code: BMIRE00027510    |    Category: Life Sciences

Available Report Formats

pdf-format excel-format pptx-format
Request Free Sample Buy Now
Europe Glycomic Therapeutics Market
Free Sample Buy Now

1. Introduction

1.1 Business Market Insights Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights
2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
  • 3.2.1 Hypothesis formulation:
  • 3.2.2 Macro-economic factor analysis:
  • 3.2.3 Developing base number:
  • 3.2.4 Data Triangulation:
  • 3.2.5 Country level data:

4. Europe Glycomic Therapeutics Market Landscape

4.1 Market Overview
4.2 Porter's Five Forces Analysis
  • 4.2.1 Bargaining Power of Suppliers
  • 4.2.2 Bargaining Power of Buyers
  • 4.2.3 Threat of New Entrants
  • 4.2.4 Competitive Rivalry
  • 4.2.5 Threat of Substitutes
4.3 Ecosystem Analysis
  • 4.3.1 Raw Material Suppliers
  • 4.3.2 Manufacturers
  • 4.3.3 Distributors/Suppliers
  • 4.3.4 End Users

5. Europe Glycomic Therapeutics Market – Key Market Dynamics

5.1 Growth Drivers
  • 5.1.1 Increasing research in glycomics
  • 5.1.2 Rising demand for personalized medicine
  • 5.1.3 Technological advancements in glycan analysis
5.2 Market Opportunities
  • 5.2.1 Expanding application in cancer treatments
  • 5.2.2 Growth in precision medicine market
  • 5.2.3 Development of glycan-based therapeutics
5.3 Future Trends
  • 5.3.1 Focus on glycan biomarker discovery
  • 5.3.2 Advancements in glycosylation research
  • 5.3.3 Integration with gene therapies
5.4 Impact of Drivers and Restraints

6. Europe Glycomic Therapeutics Market Regional Analysis

6.1 Europe Glycomic Therapeutics Market Overview
6.2 Europe Glycomic Therapeutics Market Revenue 2020-2028 (US$ Million)
6.3 Europe Glycomic Therapeutics Market Forecast Analysis

7. Europe Glycomic Therapeutics Market Analysis – by Class

7.1 Isolated and Synthetic
  • 7.1.1 Overview
  • 7.1.2 Isolated and Synthetic: Europe Glycomic Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)

8. Europe Glycomic Therapeutics Market Analysis – by Structures

8.1 Glycoproteins
  • 8.1.1 Overview
  • 8.1.2 Glycoproteins: Europe Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)
8.2 Targeting Sialic Acid
  • 8.2.1 Overview
  • 8.2.2 Targeting Sialic Acid: Europe Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)
8.3 Proteoglycans
  • 8.3.1 Overview
  • 8.3.2 Proteoglycans: Europe Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)
8.4 Targeting Glycosaminoglycans
  • 8.4.1 Overview
  • 8.4.2 Targeting Glycosaminoglycans: Europe Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)
8.5 Glycosylphosphatidylinositol-Anchored Proteins & Heparin Based Glycans
  • 8.5.1 Overview
  • 8.5.2 Glycosylphosphatidylinositol-Anchored Proteins & Heparin Based Glycans: Europe Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)
8.6 Targeting Glycosphingolipids
  • 8.6.1 Overview
  • 8.6.2 Targeting Glycosphingolipids: Europe Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

9. Europe Glycomic Therapeutics Market Analysis – by Indications

9.1 Thrombosis & Chemoprophylaxis
  • 9.1.1 Overview
  • 9.1.2 Targeting Glycosphingolipids: Europe Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)
9.2 Anaemia
  • 9.2.1 Overview
  • 9.2.2 Targeting Glycosphingolipids: Europe Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)
9.3 Anti-Adhesive & Anti-Inflammatory
  • 9.3.1 Overview
  • 9.3.2 Targeting Glycosphingolipids: Europe Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)
9.4 Cataracts
  • 9.4.1 Overview
  • 9.4.2 Targeting Glycosphingolipids: Europe Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)
9.5 Gaucher's Disease
  • 9.5.1 Overview
  • 9.5.2 Targeting Glycosphingolipids: Europe Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)
9.6 MPS-1 & IV
  • 9.6.1 Overview
  • 9.6.2 Targeting Glycosphingolipids: Europe Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)
9.7 Cancer
  • 9.7.1 Overview
  • 9.7.2 Targeting Glycosphingolipids: Europe Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)
9.8 Alzheimer's Disease
  • 9.8.1 Overview
  • 9.8.2 Targeting Glycosphingolipids: Europe Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)
9.9 Influenza Type A & B
  • 9.9.1 Overview
  • 9.9.2 Targeting Glycosphingolipids: Europe Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

10. Europe Glycomic Therapeutics Market – Europe Analysis

10.1 Europe
  • 10.1.1 Europe Glycomic Therapeutics Market Breakdown, by Key Country, 2023 and 2028 (%)
  • 10.1.1.1 Europe Glycomic Therapeutics Market – Revenue and Forecast Analysis – by Country
  • 10.1.1.1 UK: Europe Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.1.1 UK: Europe Glycomic Therapeutics Market Breakdown, by Class
    • 10.1.1.1.2 UK: Europe Glycomic Therapeutics Market Breakdown, by Structures
    • 10.1.1.1.3 UK: Europe Glycomic Therapeutics Market Breakdown, by Indications
  • 10.1.1.2 Germany: Europe Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.2.1 Germany: Europe Glycomic Therapeutics Market Breakdown, by Class
    • 10.1.1.2.2 Germany: Europe Glycomic Therapeutics Market Breakdown, by Structures
    • 10.1.1.2.3 Germany: Europe Glycomic Therapeutics Market Breakdown, by Indications
  • 10.1.1.3 France: Europe Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.3.1 France: Europe Glycomic Therapeutics Market Breakdown, by Class
    • 10.1.1.3.2 France: Europe Glycomic Therapeutics Market Breakdown, by Structures
    • 10.1.1.3.3 France: Europe Glycomic Therapeutics Market Breakdown, by Indications
  • 10.1.1.4 Russia: Europe Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.4.1 Russia: Europe Glycomic Therapeutics Market Breakdown, by Class
    • 10.1.1.4.2 Russia: Europe Glycomic Therapeutics Market Breakdown, by Structures
    • 10.1.1.4.3 Russia: Europe Glycomic Therapeutics Market Breakdown, by Indications
  • 10.1.1.5 Italy: Europe Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.5.1 Italy: Europe Glycomic Therapeutics Market Breakdown, by Class
    • 10.1.1.5.2 Italy: Europe Glycomic Therapeutics Market Breakdown, by Structures
    • 10.1.1.5.3 Italy: Europe Glycomic Therapeutics Market Breakdown, by Indications
  • 10.1.1.6 Rest of Europe: Europe Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.6.1 Rest of Europe: Europe Glycomic Therapeutics Market Breakdown, by Class
    • 10.1.1.6.2 Rest of Europe: Europe Glycomic Therapeutics Market Breakdown, by Structures
    • 10.1.1.6.3 Rest of Europe: Europe Glycomic Therapeutics Market Breakdown, by Indications

11. Competitive Landscape

11.1 Heat Map Analysis
11.2 Company Positioning and Concentration

12. Europe Glycomic Therapeutics Market Industry Landscape

12.1 Overview
12.2 Mergers and Acquisitions
12.3 Agreements, Collaborations, and Joint Ventures
12.4 New Product Launches
12.5 Expansions and Other Strategic Developments

13. Company Profiles

13.1 Intellihep Ltd
  • 13.1.1 Key Facts
  • 13.1.2 Business Description
  • 13.1.3 Products and Services
  • 13.1.4 Financial Overview
  • 13.1.5 SWOT Analysis
  • 13.1.6 Key Developments
13.2 BioMarin Pharmaceutical Inc.
  • 13.2.1 Key Facts
  • 13.2.2 Business Description
  • 13.2.3 Products and Services
  • 13.2.4 Financial Overview
  • 13.2.5 SWOT Analysis
  • 13.2.6 Key Developments
13.3 Genzyme Corporation (Sanofi)
  • 13.3.1 Key Facts
  • 13.3.2 Business Description
  • 13.3.3 Products and Services
  • 13.3.4 Financial Overview
  • 13.3.5 SWOT Analysis
  • 13.3.6 Key Developments
13.4 Bayer AG
  • 13.4.1 Key Facts
  • 13.4.2 Business Description
  • 13.4.3 Products and Services
  • 13.4.4 Financial Overview
  • 13.4.5 SWOT Analysis
  • 13.4.6 Key Developments
13.5 GlycoMar
  • 13.5.1 Key Facts
  • 13.5.2 Business Description
  • 13.5.3 Products and Services
  • 13.5.4 Financial Overview
  • 13.5.5 SWOT Analysis
  • 13.5.6 Key Developments
13.6 GlaxoSmithKline plc.
  • 13.6.1 Key Facts
  • 13.6.2 Business Description
  • 13.6.3 Products and Services
  • 13.6.4 Financial Overview
  • 13.6.5 SWOT Analysis
  • 13.6.6 Key Developments
13.7 F.Hoffmann-La Roche Ltd
  • 13.7.1 Key Facts
  • 13.7.2 Business Description
  • 13.7.3 Products and Services
  • 13.7.4 Financial Overview
  • 13.7.5 SWOT Analysis
  • 13.7.6 Key Developments

14. Appendix

14.1 About Business Market Insights

The List of Companies - Europe Glycomic Therapeutics Market

  1. Intellihep Ltd                                                      
  2. BioMarin Pharmaceutical Inc.                    
  3. Genzyme Corporation (Sanofi)                 
  4. Bayer AG                                                            
  5. GlycoMar                                                           
  6. GlaxoSmithKline plc.           
  7. F. Hoffmann-La Roche Ltd                           
europe-glycomic-therapeutics-market